CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia by Lenk, Lennart et al.
ARTICLE
CD79a promotes CNS-infiltration and leukemia
engraftment in pediatric B-cell precursor acute
lymphoblastic leukemia
Lennart Lenk1, Michela Carlet2, Fotini Vogiatzi1, Lea Spory1, Dorothee Winterberg1, Antony Cousins 3,
Michaela Vossen-Gajcy1, Olta Ibruli1, Christian Vokuhl4, Gunnar Cario1, Omar El Ayoubi5, Lisa Kramer5,
Matthias Ritgen6, Monika Brüggemann6, Robert Häsler7, Martin Schrappe1, Stephan Fuhrmann 8,
Christina Halsey 3, Irmela Jeremias 2,9,10, Elias Hobeika5, Hassan Jumaa 5, Ameera Alsadeq 5,11 &
Denis M. Schewe 1,11✉
Central nervous system (CNS) involvement remains a challenge in the diagnosis and treat-
ment of acute lymphoblastic leukemia (ALL). In this study, we identify CD79a (also known as
Igα), a signaling component of the preB cell receptor (preBCR), to be associated with CNS-
infiltration and –relapse in B-cell precursor (BCP)-ALL patients. Furthermore, we show that
downregulation of CD79a hampers the engraftment of leukemia cells in different murine
xenograft models, particularly in the CNS.
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CNS-involvement is routinely assessed by microscopy of thecerebrospinal fluid (CSF)1, an approach that is limited inperformance and informative value. Irrespective of the
initial CNS status, all patients are treated with intrathecal che-
motherapy which can be neurotoxic2. Hence, besides conclusive
diagnostic markers, novel targets for specific eradication of leuke-
mia cells in the CNS have to be established. In B-cell precursor
(BCP)-ALL, certain cytogenetic alterations such as the t(1;19)
translocation leading to the E2A-PBX1 fusion and the t(9;22)
translocation causing the BCR-ABL fusion (Philadelphia-chromo-
some) are associated with a higher incidence of CNS-leukemia1,3,4.
Recently we have reported that ZAP70 and the Interleukin-7
receptor (IL7R) are associated with CNS-involvement in BCP-
ALL5,6. Both proteins are closely associated with the preBCR sig-
naling pathway. The preBCR is composed of the heavy chain (µ),
the surrogate light chain (VpreB and λ5) and the signaling com-
ponents CD79a (Igα) and CD79b (Igβ)7. Activation of the preBCR
results in the phosphorylation of tyrosine residues within the
immunoreceptor tyrosine-based activation motifs (ITAMs) of the
cytoplasmic tails of CD79a/CD79b. This is followed by subsequent
recruitment and activation of Src homology kinases, such as LYN
and FYN as well as spleen tyrosine kinase (SYK) and ZAP708.
Evidence suggesting that the preBCR is involved in the patho-
genesis of lymphoid malignancies is accumulating9. Hence, we
hypothesized that the preBCR-signaling complex itself is important
for CNS-infiltration.
Results and discussion
CD79a has independent prognostic relevance for CNS-
involvement and CNS-relapse in BCP-ALL patients. To inves-
tigate this, we first measured CD79a mRNA levels in diagnostic
bone marrow (BM) samples (70–99.5% blasts), in a cohort of 100
pediatric BCP-ALL patients5. This cohort was selectively designed
to contain a high number of CNS-positive patients as only 3–5%
of patients are CNS-positive upon initial diagnosis and CNS
involvement is thus a rare event1,10. We found that CD79a levels
significantly correlated with ZAP70 and with IL7R mRNA levels
in bivariate correlation analyses (Fig. 1a, b). Furthermore, we
found that patients diagnosed as CNS-positive showed sig-
nificantly higher levels of CD79a than patients diagnosed as CNS-
negative (median CD79a expression: 5.183 ± 0.396 in CNS− vs.
7.537 ± 1.278 in CNS+; Supplementary Fig. 1a, logarithmic scale).
Importantly, multivariate logistic regression analysis, excluding
the effect of known parameters associated with CNS-infiltration,
showed that a CD79a expression above the 75th percentile was
associated with a significant ~8-fold increased risk for CNS-
positivity compared to the lower quartile (odds ratio= 7.873, 95%
confidence interval (CI) [1.338,46.312], p= 0.022, Fig. 1c). CD79a
expression levels above the 25th and 50th percentiles were also
linked with CNS-involvement (Fig. 1c). Multivariate logistic
regression analysis comparing the lower quartile to the second,
third and fourth quartiles in CD79a expression revealed a sig-
nificant 7-fold increased risk for CNS-positivity for patients with
CD79a expression levels above the 25th percentile (odds ratio=
7.0, 95% CI [1.4,33.9], p= 0.016, Supplementary Fig. 1b) sug-
gesting that CD79a up-regulation increases the risk for CNS-
positivity.
Next, we investigated the association between CD79a and
CNS-relapse in an independent cohort from the TARGET phase
1 data set containing gene expression data of more than 200 BCP-
ALL cases. We found that an increased expression of CD79a (z-
score ≥ 1.2) was associated with significantly reduced long-term
probability rates for isolated-CNS-relapse-free survival (Fig. 1d).
When analyzing all relapse cases associated with the CNS
(combined and isolated), we found that high CD79 levels are
associated with a tendency towards reduced CNS-relapse-free-
survival (Supplementary Fig. 1c). We found no significant
difference for BM-relapse-free probability rates between CD79a
high and CD79a low patients further suggesting that CD79a is
particularly important for CNS-relapse (Supplementary Fig. 1d).
We then asked if ALL cells retrieved from the CNS show
elevated CD79a expression levels. For this approach we xeno-
transplanted NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) with diag-
nostic BM samples of seven different E2A-PBX+ patients
(Supplementary Table 1, patients 1–7) and recovered PDX-ALL
cells from different organs.
In line with previous reports11, PDX animals exposed some
degree of meningeal engraftment, supporting the view that most
ALL cells are in principle capable of invading the CNS. Indeed,
we found a significant upregulation of CD79a in ALL cells from
the CNS as compared to spleen PDX cells (Fig. 1e). Moreover, we
found increased levels of CD79a in CNS-ALL cells compared to
SP-ALL cells in 4/5 mice transplanted with PDX samples of
further BCP-ALL subtypes (3×“B-other”, 1×BCR-ABL+, 1×hyper-
diploid, Supplementary Table 1, patients 8–12) as well as in a
mouse transplanted with the highly CNS-tropic TEL-AML1+ cell
line REH (Fig. 1f).
Taken together, our data show that high expression levels of
CD79a are associated with CNS-involvement in BCP-ALL
patients of different cytogenetics indicating that CD79a, in
conjunction with other markers, could be used as surrogate
marker for the assessment of CNS-involvement in BCP-ALL.
Furthermore, our data imply that CD79a is upregulated in ALL
cells from the CNS in BCP-ALL xenograft models. Moreover, we
observed that CD79a mRNA levels strongly correlate with mRNA
levels of CD79b in our BCP-ALL patient cohort (Supplementary
Fig. 1e) and that CD79b is upregulated in ALL cells recovered
from the CNS versus SP from NSG-mice bearing E2A-PBX1-
PDX cells (Supplementary Table 1, patients 1–7, Supplementary
Fig. 1f) indicating that CD79b is also important for CNS
involvement in BCP-ALL.
CD79a is required for leukemic engraftment particularly in the
CNS. Previous reports suggest that some BCP-ALL subtypes, e.g.
E2A-PBX1+ BCP-ALL critically depend on preBCR signaling,
and that others, including BCR-ABL+ BCP-ALL, progress irre-
spectively of a functional preBCR and are considered as preBCR
negative12.
To further investigate this issue and the role of CD79a in CNS
involvement in vivo we utilized two cell lines 697 (E2A-PBX1+)
and SUP-B15 (BCR-ABL+) representing preBCR-positive and
preBCR-negative BCP-ALL cells. First, we performed short-
hairpin RNA-interference-mediated knockdown of CD79a in the
human cell lines (Supplementary Fig. 2a). Control cells (carrying
shRNA against a target sequence from Renilla spp., shCtr) and
cells carrying CD79a shRNA (shCD79a) were injected into NSG
mice and leukemia engraftment in different organs was analyzed.
Indeed, animals injected with 697-shCD79a cells exposed a
significant reduction of leukemic burden in the CNS (4/15 CNS+
animals, 26%) as compared to animals injected with control cells
(7/10 CNS+ animals, 70%) (Fig. 2a). In contrast, leukemic
infiltration in spleen and BM, as well as survival times, were
comparable between both groups (Supplementary Fig. 2b–d).
SUP-B15-shCD79a cells xenografted into NSG mice showed
similar engraftment in the spleens and BMs as compared to SUP-
B15-shCtrl cells (Supplementary Fig. 2e, f). However, animals
injected with SUP-B15-shCD79a cells only showed weak infiltra-
tion of the leptomeninges whereas SUP-B15-shCtrl cells caused
pronounced and multi-layered CNS-leukemia (Fig. 2b). Further-
more, animals injected with SUP-B15-shCD79a cells exposed a
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small but significant prolongation of median mouse survival by
12 days (Supplementary Fig. 2g), which is most likely due to the
delay in development of CNS-leukemia. Together these data
indicate an important role of CD79a for the engraftment of E2A-
PBX1+ (preBCR-positive) and BCR-ABL+ (preBCR-negative)
BCP-ALL cells in that niche.
To further substantiate the role of CD79a in CNS-involvement,
CD79a knockdown experiments were performed using BCP-ALL
PDX primary cells. PDX cells from an E2A-PBX1+ patient
(Supplementary Table 1, patient 5) were stably transduced with
lentiviral constructs harboring either a blue fluorescent protein
(BFP) or a green fluorescent protein (GFP) reporter gene cassette.
BFP cells were then stably transduced with a second vector which
carried a dsRED-reporter gene coupled to the control shRNA
described above (PDX-shCtr), whereas GFP cells were transduced
with dsRED-reporter gene fused with a CD79a shRNA (PDX-
shCD79a). Both cell types were then injected into NSG mice in a
1:1 ratio to study whether CD79a provides a niche-specific
engraftment advantage (Fig. 2c, Supplementary Fig. 3a, b).
Indeed, upon clinical signs of overt leukemia, significant
variations in the percentage of engrafted populations of PDX-
shCD79a compared to PDX-shCtr were observed in the spleen
Fig. 1 CD79a has independent prognostic relevance for CNS-involvement and CNS-relapse in BCP-ALL patients. a–c CD79a mRNA levels and further
genes (all normalized to mRNA levels in the 697 cell line) were measured in diagnostic BM samples in a selected cohort of 100 pediatric BCP-ALL patients
of mixed cytogenetics which contained 28 CNS-positive patients matched to 72 CNS-negative patients of corresponding sex and age5. a, b Bivariate
correlation analysis between CD79a expression and a ZAP70 and b Interleukin-7-receptor (IL7R) were performed, Spearman correlation (two-tailed,
respective 95% confidence interval (CI) [0.08789, 0.4605] and [0.2174, 0.5616]). c Univariate and multivariate logistic regression analysis for risk of
initial CNS-involvement, controlled for age and white blood cell (WBC) count at diagnosis as well as TEL-AML and BCR-ABL positivity. *Based on
expression as measured by RT-PCR of patient material at initial diagnosis. †Multivariate OR controlled for age and WBC count at diagnosis as well as TEL-
AML and BCR-ABL positivity. §Reference category. Definitions of patient CNS status in Supplementary Material d Kaplan–Meier survival curve showing
reduced isolated CNS-relapse-free survival in children with upregulated CD79a gene expression in diagnostic BM/peripheral blood (upregulation is defined
as z-score for gene expression ≥1.2 which is equivalent to the 11.5% top CD79a-expressing patients; TARGET phase 1 dataset). e E2A-PBX1+ BCP-ALL
blasts from seven different patient-derived xenograft (PDX) samples were injected into NSG mice ALL cells were recovered from spleen (SP) and CNS and
subjected to quantitative real-time PCR (qPCR). QPCR shows the upregulation of CD79a at the transcription level in PDX cells recovered from the CNS
relative to cells isolated from Sp, Mann–Whitney-U test, two-tailed, graphs show mean with standard error of n= 7 independent samples. f An
upregulation of CD79a was also observed in CNS-BCP-ALL cells compared to SP-BCP-ALL cells in NSG-mice injected with bone marrow cells from BCP-
ALL patients of different cytogenetic backgrounds (n= 5 independent patient samples) or CNS-tropic REH cells (TEL-AML1) as determined via qPCR.
Relative quantification of CD79a mRNA levels normalized to 697 cells are shown for individual patients, P Patient, AU Arbitrary units. *P < 0.05, **P≤ 0.01,
***P≤ 0.001.
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(12% vs. 88%), the BM (28% vs. 72%), and the CNS (2% vs. 98%)
(Fig. 2d). Of note, the proportion of PDX-shCD79a to PDX-shCtr
cells was significantly lower in PDX cells recovered from the CNS
as compared to other organs (Fig. 2d, e) indicating an important
role for CD79a for leukemia engraftment in mice, particularly in
the CNS.
The role of CD79a in BCR-ABL+ ALL was further analyzed
using a murine/murine transplantation model. BM cells were
isolated from mice carrying either a LoxP-flanked variant of the
Mb1-wildtype gene, which codes for CD79a (Mb1fl/fl; CD79a-
Ctrl), or from CD79a knock-out mice (Mb1Cre/Cre; CD79a-KO)13
(Supplementary Fig. 4a). Cells were cultured for 3 days in the
presence of IL7, an essential growth factor for early B-cells14.
Subsequently, cells were transduced with a retroviral vector for
BCR-ABL1 expression and cultured independent of IL7 to ensure
malignant transformation15. CD79a-KO cells proliferated at a
similar rate in vitro as compared to control (Supplementary
Fig. 4b). Cells were then injected into mice. Transformed cells led
to overt leukemia in mice within 29 days (exemplary BM smear in
Supplementary Fig. 4c). In contrast, we found that animals
injected with BCR-ABL1+ pro-B-cells lacking CD79a exhibited a
significant delay in leukemic engraftment in the spleen, BM, and
CNS (Fig. 2f, Supplementary Fig. 4d, e). No animal of the CD79a-
KO group sacrificed on day 29 displayed signs of CNS-infiltration
(Supplementary Fig. 4e). Importantly, animals injected with
CD79a-KO cells showed a highly significant median survival
prolongation of 66 days compared to mice injected with CD79a-
Ctr cells (29 days vs. 95 days, Fig. 2g). These results suggest that
whereas low expression levels of CD79a result in an engraftment
disadvantage in the CNS, complete absence of CD79a impacts the
Fig. 2 CD79a is required for leukemia engraftment and CNS-involvement in vivo. a, b One million E2A-PBX1+ 697 cells or BCR-ABL+ SUP-B15 ALL cells
bearing an shRNA against CD79a (shCD79) or a control shRNA (shCtr) were injected into NSG mice and animals sacrificed when the first mouse showed
signs of overt leukemia (detection of >75% leukemic blasts in the peripheral blood or clinical signs of leukemia including loss of weight or activity,
organomegaly, hind-limb paralysis). Semi-quantitative scoring of CNS-involvement of a 697 and b SUP-B15 cells was employed4, Fisher’s exact test, two-
tailed. c–e CD79a shRNA (GFP) or a control shRNA (BFP) were introduced in E2A-PBX1 positive patient cells. A total number of 2 × 106 cells (1:1 ratio of
both cell types) were xenografted into NSG mice (n= 8 animals) in a competitive experiment (c). Mice were sacrificed upon appearance of leukemic
symptoms. d The count of ALL-PDX cells in spleen (Sp), bone marrow (BM), and CNS was assessed via flow cytometry and the percentages of cells
bearing either shCD79 or shCtr were calculated (Sp shCtr vs. shCD79a ***P < 0.0001, BM shCtr vs. shCD79a ***P= 0.0002, CNS shCtr vs. shCD79a
***P < 0.0001) e, two-tailed t-tests, graphs show mean with standard error. f and g Mouse pro/pre-B-cells isolated from bone marrow of either wildtype
(Ctr,Mb1fl/fl) or CD79a knockout (Mb1Cre/Cre, CD79a-KO) were transformed with BCR-ABL1 and injected into NSG mice (n= 6 Ctr animals, n= 12 CD79a-
KO animals). n= 6 Ctr and n= 6 CD79a-KO animals were sacrificed when the control mice showed signs of overt leukemia. One group of CD79a-KO mice
(n= 6 animals) was maintained for survival analysis. f percentages of leukemic cells in Sp and BM of NSG mice xenografted with Ctr or CD79a-KO cells
were determined (Sp Ctr vs. CD79a KO **P= 0.0050, BM Ctr vs. CD79a KO **P= 0.0049). g Differences in survival of animals injected with Ctr cells
(n= 6 animals) vs. CD79a-KO cells (n= 6 animals) were determined using Kaplan–Meier log-rank statistics. *P < 0.05, **P≤ 0.01, ***P≤ 0.001.
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overall engraftment of BCP-ALL cells in vivo. These findings are
intriguing as previous studies have underestimated the role of
preBCR signaling in BCP-ALL, particularly for subgroups which
are considered preBCR negative, as they lack an assembled
preBCR complex on the surface, such as BCR-ABL+ ALL12. Here
we provide evidence that the signaling molecules of the preBCR
are indispensable for leukemia development and CNS involve-
ment. Supporting this view, ZAP70, PI3K, and MAPK pathways,
which all act downstream the preBCR were shown to be directly
involved in CNS involvement5,16,17. Furthermore, molecules
associated with the adherence to vascular and conjunctive tissue
in the meningeal microenvironment such as α6 integrin and
VEGF were reported to promote CNS infiltration and survival in
the CNS niche16,18. Hence, we assume that molecules highly
abundant in the meningeal microenvironment interact with ALL
cells and promote adherence and survival signaling in the CNS by
crosstalk with the preBCR-signaling complex10. Yet, our results
do not necessarily apply to the relapse situation, as we did not
find increased CD79a levels in samples obtained at CNS relapse
when analyzing six matched pairs of diagnostic BM samples and
CNS-relapse samples in our BCP-ALL cohort. So far, small
molecule inhibitors were used to regulate preBCR downstream
signaling12,16,19. Our study promotes the view that one could also
modulate this pathway by targeting the receptor itself. In this
regard, IgM and CD79b antibodies, the latter being used in
lymphoma treatment, may be effective options20. We found that
not only CD79a, but also its dimerization partner CD79b is
upregulated in PDX-ALL cells isolated from the CNS of
xenotransplanted mice. Accordingly, prospective measurements
of CD79a and CD79b in patient samples will help to validate the
role of these molecules in CNS involvement in BCP-ALL.
Overall, using different pre-clinical mouse models of BCP-ALL,
we show that absence of the preBCR signaling unit CD79a is
associated with an attenuation of leukemic infiltration, particu-
larly in the CNS. Hence, CD79a may represent a promising target
for novel diagnosis and treatment approaches in CNS leukemia.
Methods
Patient samples and human cell lines. BCP-ALL patients were treated according
to ALL-Berlin-Frankfurt-Münster (BFM) 2000 or 2009 protocols after informed
consent in accordance with the Declaration of Helsinki. Our study was approved by
the ethical committee of the Christian-Albrechts-University Kiel (D437/17). 697,
SUP-B15, and REH cells were obtained from DSMZ. Authentication of cell lines
was performed using flow cytometry (BCP-ALL markers such as hCD19, hCD45)
and RT-PCR was used to confirm the chromosomal translocation for BCR-ABL in
SUP-B15 cells. All cell lines were regularly tested for absence of mycoplasma
contamination using the MycoAlert™ Mycoplasma Detection Kit (Lonza).
BCP-ALL xenografts and isolation of PDX cells from different niches. NOD.
Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were purchased from Charles River and
xenografts generated in accordance with governmental regulations (Schleswig-
Holstein Ministerium für Energiewende, Landwirtschaft, Umwelt, Natur und
Digitalisierung)4–6,21. One million ALL cells were injected intravenously into
female NSG-mice (6–10 weeks of age) and leukemic engraftment was followed by
detection of human CD45+/murine CD45−/human CD19+ cells in the peripheral
blood via flow cytometry analysis. Animals were sacrificed when showing signs of
overt leukemia (detection of >75% leukemic blasts in the peripheral blood or
clinical signs of leukemia including loss of weight or activity, organomegaly, hind-
limb paralysis). Leukemic infiltration of the murine CNS was assessed in histolo-
gical sections in blinded experiments and the scorings CNS− (no CNS infiltration
of the leptomeninges), CNS+ (week infiltration of the leptomeninges) and CNS++
(strong and multilayered meningeal infiltration) were discriminated4,6. For the
recovery of ALL cells from murine organs, mice were sacrificed by CO2 inhalation
and spleens, hind leg bones and heads were collected. BM cells were isolated by
flushing out the bones using a 27 G syringe. For extraction of the meninges, mouse
skulls were opened, brains extracted and the meninges were carefully detached
from the skull with tweezers. Spleen and CNS were homogenized using a 70 µm
Nylon cell strainer. Spleen, BM, and CNS cells were subjected to red blood cell lysis,
washed with PBS and purity of ALL cells was assessed via flow cytometry detecting
human CD45, murine CD45, and human CD19.
Flow cytometry. A minimum of 1 × 106 cells were used for flow cytometry
staining. Intracellular flow cytometry staining was performed using the Fixation/
Permeabilization Solution Kit (BD Bioscience). Cell viability was measured using
Sytox® blue dead cell stain (Life Technologies). A FACS Canto II (BD Biosciences)
or a MACSQuant X (Miltenyi Biotec) were used for flow cytometry. FlowJo v.10.7
was used for data analysis. Detailed information on the gating strategy is provided
in Supplementary Fig. 5. Antibodies for flow cytometry (hCD19, hCD45, mCD45,
and CD79a) were purchased from BioLegend. Detailed information on antibodies
used for flow cytometry analysis is provided in Supplementary Table 2
Statistics and reproducibility. Statistical analysis was performed using GraphPad
PRISM 5.00, SPSS 22, SigmaPlot 12.5, and/or R v.3.3.3. Gaussian distribution was
tested using the Shapiro–Wilk test. Statistical significance was assessed using an
unpaired t-test, a Mann–Whitney test or ANOVA, depending on normal dis-
tribution and group numbers. Differences in survival were calculated using
Kaplan–Meier log-rank statistics. A P-value of <0.05 was considered significant.
The number (n) of independent biological replicates (at least n= 3) are indicated
in the figure captions. Associations between gene expression and CNS status were
examined by unconditional logistic regression to calculate odds ratios (ORs) and
95% CIs or using Cox proportional Hazards Model5,22. Bivariate correlations were
analyzed calculating the Spearman correlation coefficient5.
Gene expression datasets for re-evaluation. For analysis of CNS relapse in
patients, the dataset from the United States National Cancer Institute “TARGET
phase 1 ALL Project” was used23. Microarray data from diagnostic BM (n= 131
independent patient samples) or peripheral blood (n= 76 independent patient
samples) of children with high risk BCP-ALL annotated with clinical follow-up
data including CNS-relapse were thereby analyzed24,25. The dbGaP data is available
via the dbGaP accession phs000218.v21.p7. The microarray data was log-
transformed and z-scores calculated for CD79a. CD79a upregulation was defined
as a z-score for gene expression ≥1.2 (TARGET phase 1 data set). This is equivalent
to the top 11.5% CD79a-expressing patients.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data supporting the findings of this study are available within the article and its
supplementary information files (Supplementary Information and Supplementary
Data 1). The results published here are in part based upon data generated by the
Therapeutically Applicable Research to Generate Effective Treatments (https://ocg.
cancer.gov/programs/target) initiative, phs000218. The data used for this analysis are
available at https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?
study_id=phs000218.v21.p7 (dbGaP accession: phs000218.v21.p7) managed by the
United States National Cancer Institute (NCI). Microarray data used for the analysis are
available on [ftp://caftpd.nci.nih.gov/pub/OCG-DCC/TARGET/ALL/clinical/Phase1/;
microarray GEO accession GSE11877].
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